Transcatheter aortic valve implantation for degenerative aortic valve regurgitation long after heart transplantation

  • D. Z
  • I. A
  • T. B
  • et al.
N/ACitations
Citations of this article
4Readers
Mendeley users who have this article in their library.

Abstract

Transcatheter aortic valve implantation (TAVI) has become a feasible therapeutic option for the management of high-risk patients with severe degenerative aortic stenosis. Recently it has been extended to high-risk patients with severe aortic regurgitation. Degenerative aortic valve disease is generally uncommon in heart transplant recipients. We report the case of a 75-year-old man in whom severe degenerative aortic regurgitation developed 14 years after heart transplantation (HTx). Because of multiple comorbidities and high surgical risk, TAVI was preferred. A 29-mm CoreValve prosthesis (Medtronic Inc, Minneapolis, MN) was successfully implanted using a transfemoral approach. © 2013 by The Society of Thoracic Published by Elsevier Inc.

Cite

CITATION STYLE

APA

D., Z., I., A., T., B., L., S., G., B., R., M., … U., L. (2013). Transcatheter aortic valve implantation for degenerative aortic valve regurgitation long after heart transplantation. Annals of Thoracic Surgery. I. Armellini, Department of Cardiology, Santa Maria della Misericordia Hospital, Piazzale Santa Maria della Misericordia, n 15, Udine, UD 33100, Italy. E-mail: ilaria.armellini@libero.it: Elsevier USA (6277 Sea Harbor Drive, Orlando FL 32862 8239, United States). Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&AN=2013695831

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free